Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Opiren

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 92Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
    Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

    09 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/09/3058308/18362/en/Amarin-Confirms-Effective-Date-for-1-For-20-ADS-Ratio-Change.html

    GLOBENEWSWIRE
    09 Apr 2025
    Share Share
    Amarin Appoints Michael Torok to Board
    Amarin Appoints Michael Torok to Board

    07 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/07/3056586/18362/en/Amarin-Appoints-JEC-Capital-Partners-Michael-Torok-to-Board-of-Directors.html

    GLOBENEWSWIRE
    07 Apr 2025
    Share Share
    Amarin Shares Data On EPA In Lp(a) Plasma, GLP-1 Combination
    Amarin Shares Data On EPA In Lp(a) Plasma, GLP-1 Combination

    31 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/31/3052239/18362/en/Amarin-Highlights-Recent-Data-Presented-at-ACC-25-Evaluating-Mechanistic-Effects-of-Eicosapentaenoic-Acid-EPA-in-Lp-a-Enriched-Plasma-and-in-Combination-with-GLP-1-Agonist.html

    GLOBENEWSWIRE
    31 Mar 2025
    Share Share
    Study: EPA & GLP-1 Effects On Lp(a) To Be Presented At ACC
    Study: EPA & GLP-1 Effects On Lp(a) To Be Presented At ACC

    19 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/19/3045269/18362/en/New-Research-Exploring-Mechanistic-Benefits-of-Eicosapentaenoic-Acid-EPA-In-Vitro-on-Lipoprotein-a-Lp-a-Oxidation-and-on-Protein-Expression-in-Endothelial-Cells-in-Combination-with.html

    GLOBENEWSWIRE
    19 Mar 2025
    Share Share
    Amarin Plans ADR Ratio Change Under Its Depository Receipt Program
    Amarin Plans ADR Ratio Change Under Its Depository Receipt Program

    12 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/12/3041242/18362/en/Amarin-Announces-Plan-to-Initiate-a-Ratio-Change-Under-Its-American-Depository-Receipt-ADR-Program.html

    GLOBENEWSWIRE
    12 Mar 2025
    Share Share
    Amarin Reports Q4 Results, Business Update, Announces Corporate Action
    Amarin Reports Q4 Results, Business Update, Announces Corporate Action

    12 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/12/3041230/18362/en/Amarin-Reports-Fourth-Quarter-Financial-Results-Business-Update-and-Announces-Important-Corporate-Action.html

    GLOBENEWSWIRE
    12 Mar 2025
    Share Share